The subsidiary of Sinotherapeutics Inc. (688247.SH), Xuantai Pharmaceuticals, has obtained EU GMP certification.

Sinotherapeutics Inc. (688247.SH) announced that its wholly-owned subsidiary, Jiangsu Xuantai Pharmaceutical Co., Ltd. (referred to as "Xuantai Pharmaceutical"), recently received the "Drug GMP Certificate" issued by the National Public Health and Pharmaceutical Center of Hungary in accordance with the relevant regulations of the European Medicines Agency (EMA). This latest GMP certification by the EU's EMA, following previous certifications by the NMPA (China National Medical Products Administration), FDA (U.S. Food and Drug Administration), PMDA (Pharmaceuticals and Medical Devices Agency of Japan), SFDA (Saudi Food and Drug Authority), among other regulatory authorities, demonstrates the company's consistent alignment with international standards in terms of quality systems. This will strongly promote the expansion of the company's products in overseas markets, enhance the company's market competitiveness, and continue to support the company in providing one-stop formulation research and development production services to global pharmaceutical and biotechnology companies, thereby providing strong support for gaining customer recognition.